Lonza Sales Grow on New Contract Momentum
By Billy Gray
Lonza said sales grew in 2025 on the strength of new commercial contracts across technology programs.
The healthcare manufacturer and contract-development group on Wednesday reported 2025 sales of 6.53 billion Swiss francs, equivalent to $8.58 billion, up 19.2% compared with 2024. Analysts saw sales for the year at 7.54 billion francs, according to consensus estimates compiled by Vara Research.
Lonza highlighted contract activity at its biologics manufacturing site in Vacaville, Calif., as a reason for its solid performance.
The company reported 2025 core earnings before interest, taxes, depreciation and amortization of 2.06 billion francs, a 24.9% increase from 2024. Analysts had forecast core Ebitda of 2.27 billion francs, according to Vara Research.
Lonza said that in the current year it expects sales growth of 11% to 12% at constant currencies and further core Ebitda margin expansion, reaching a level above 32%.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
January 28, 2026 01:15 ET (06:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States